Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.KRRO · Entity 6388 | Director | June 11, 2024 | June 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date June 11, 2024 · Filed June 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.19 · Expires 2034-06-10 | Direct | 5,190 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 5,190 · Balance 5,190 F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2023 Filed Jul 11, 2023 21:24 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 9,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020571 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 445,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 21:24 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,634 | $0.35 | $921.90 |
DisclosureSEC source: 0001127602-23-020571 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,196 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.34 to $0.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 07, 2023 Filed Jul 13, 2023 01:22 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,634 | $0.35 | $921.90 |
DisclosureSEC source: 0000950170-23-032737 · ownership.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 718,014 F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.34 to $0.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 9,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020474 · form4.xml · derivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,818 Underlying: Common Stock · 9,091 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive on share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive on share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F4 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 9,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020474 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive on share of Issuer common stock. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,773 | $0.34 | $942.82 |
DisclosureSEC source: 0001127602-23-020474 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,739 F2 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.33 to $0.35. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 06, 2023 Filed Jul 13, 2023 01:16 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,773 | $0.34 | $942.82 |
DisclosureSEC source: 0000950170-23-032731 · ownership.xml · nonDerivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 720,648 F2 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.33 to $0.35. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Unit · Derivative | 9,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020474 · form4.xml · derivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,909 Underlying: Common Stock · 9,091 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive on share of Issuer common stock. F1 · price: Each restricted stock unit represents a contingent right to receive on share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F4 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:56 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 9,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020474 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive on share of Issuer common stock. Read SEC document |
| July 04, 2023 Filed Jul 13, 2023 01:16 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionRestricted Stock Units · Derivative | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-032731 · ownership.xml · derivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The Restricted Stock Units vested on July 4, 2023 and do not have an expiration date. F4 · derivative.expiration_date: The Restricted Stock Units vested on July 4, 2023 and do not have an expiration date. Read SEC document |
| July 04, 2023 Filed Jul 13, 2023 01:16 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-032731 · ownership.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 723,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 03, 2023 Filed Jul 13, 2023 01:16 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | GiftCommon Stock | 33,345 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-032731 · ownership.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423,421 Read SEC document |
| February 01, 2023 Filed Jul 13, 2023 01:16 UTC Amendment | Korro Bio, Inc. FREQ · Entity 6388 | GiftCommon Stock | 13,345 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-032731 · ownership.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,766 Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 280,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002460 · form4.xml · derivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. F2 · derivative.expiration_date: The restricted stock units will vest in four equal annual installments beginning on January 26, 2024. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 200,000 | Not disclosed Strike: $35.85 | Not disclosed |
DisclosureSEC source: 0001127602-22-021377 · form4.xml · derivative · entry 6 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2031-01-14 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 200,000 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021377 · form4.xml · derivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-01-14 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 242,500 | Not disclosed Strike: $25.05 | Not disclosed |
DisclosureSEC source: 0001127602-22-021377 · form4.xml · derivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 242,500 shares Expires 2030-02-11 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024 Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 242,500 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021377 · form4.xml · derivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,500 Underlying: Common Stock · 242,500 shares Expires 2030-02-11 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024 Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 714,413 | Not disclosed Strike: $14.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-021377 · form4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 714,413 shares Expires 2029-10-01 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 714,413 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021377 · form4.xml · derivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,413 Underlying: Common Stock · 714,413 shares Expires 2029-10-01 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:18 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005758 · form4.xml · derivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive on share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023. F2 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 13:33 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 6,905 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-22-001609 · form4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,905 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 13:33 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 6,905 | $0.61 | $4,212.05 |
DisclosureSEC source: 0001127602-22-001609 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:03 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 6,905 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-031694 · form4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,905 Underlying: Common Stock · 6,905 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:03 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 6,905 | $0.61 | $4,212.05 |
DisclosureSEC source: 0001127602-21-031694 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:48 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 6,905 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-028414 · form4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,810 Underlying: Common Stock · 6,905 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:48 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 6,905 | $0.61 | $4,212.05 |
DisclosureSEC source: 0001127602-21-028414 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 20:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 6,905 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-026798 · form4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,715 Underlying: Common Stock · 6,905 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 20:13 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 6,905 | $0.61 | $4,212.05 |
DisclosureSEC source: 0001127602-21-026798 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 6,905 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-025022 · form4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,620 Underlying: Common Stock · 6,905 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:06 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 6,905 | $0.61 | $4,212.05 |
DisclosureSEC source: 0001127602-21-025022 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 6,905 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-023168 · form4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,525 Underlying: Common Stock · 6,905 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 6,905 | $0.61 | $4,212.05 |
DisclosureSEC source: 0001127602-21-023168 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:22 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 6,905 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-021567 · form4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,430 Underlying: Common Stock · 6,905 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:22 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 6,905 | $0.61 | $4,212.05 |
DisclosureSEC source: 0001127602-21-021567 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 113,690 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-020524 · form4.xml · derivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,335 Underlying: Common Stock · 113,690 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 113,690 | $0.61 | $69,350.90 |
DisclosureSEC source: 0001127602-21-020524 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 9,416 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-008932 · form4.xml · derivative · entry 7 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,025 Underlying: Common Stock · 9,416 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 192 | $52.11 | $10,004.89 |
DisclosureSEC source: 0001127602-21-008932 · form4.xml · nonDerivative · entry 6 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F6 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $52.08 to $52.14. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,202 | $51.76 | $217,491.74 |
DisclosureSEC source: 0001127602-21-008932 · form4.xml · nonDerivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,278 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $51.05 to $51.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,688 | $50.00 | $134,410.21 |
DisclosureSEC source: 0001127602-21-008932 · form4.xml · nonDerivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,480 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $49.53 to $50.37. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,255 | $48.85 | $61,311.27 |
DisclosureSEC source: 0001127602-21-008932 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,168 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $48.33 to $49.06. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,079 | $47.84 | $51,617.85 |
DisclosureSEC source: 0001127602-21-008932 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,423 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $47.17 to $48.16. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 9,416 | $0.61 | $5,743.76 |
DisclosureSEC source: 0001127602-21-008932 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 16,554 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-004975 · form4.xml · derivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,441 Underlying: Common Stock · 16,554 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 5,518 | $57.50 | $317,285.00 |
DisclosureSEC source: 0001127602-21-004975 · form4.xml · nonDerivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 5,518 | $55.00 | $303,490.00 |
DisclosureSEC source: 0001127602-21-004975 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,604 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 5,518 | $52.50 | $289,695.00 |
DisclosureSEC source: 0001127602-21-004975 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,122 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 16,554 | $0.61 | $10,097.94 |
DisclosureSEC source: 0001127602-21-004975 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 12:44 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 11,036 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-004085 · form4.xml · derivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,995 Underlying: Common Stock · 11,036 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.